Cuprina Holdings (Cayman) Limited Class A (CUPR)
NASDAQ:CUPR
Want to see CUPR full AI Analyst Report?
Top Page
Cuprina Holdings (Cayman) Limited Class A
(NASDAQ:CUPR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$8.50
▲(2136.84% Upside)
Action:Reiterated
Date:06/16/26
The score is primarily held down by weak financial performance—persistent losses, negative free cash flow, and a sharp increase in 2025 cash burn—despite modest leverage and improved equity in 2025. Technicals are a relative positive with a strong trend above major moving averages, but valuation is constrained by a negative P/E and no dividend yield.
Positive Factors
FDA 510(k) clearance
The FDA 510(k) clearance is a durable regulatory milestone that creates a U.S. commercial pathway and a global benchmark for the product. It supports sustainable revenue potential in chronic wound care, strengthens clinician acceptance, and lowers regulatory risk for future market expansions.
Negative Factors
Negative cash flow trend
Persistent negative operating and free cash flow, with a marked increase in 2025 burn, signals structural funding reliance. Without sustained revenue improvements or cost reduction, the company will need repeated external financing, raising dilution risk and limiting long-term operational autonomy.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA 510(k) clearance
The FDA 510(k) clearance is a durable regulatory milestone that creates a U.S. commercial pathway and a global benchmark for the product. It supports sustainable revenue potential in chronic wound care, strengthens clinician acceptance, and lowers regulatory risk for future market expansions.
Read all positive factors
Cuprina Holdings (Cayman) Limited Class A (CUPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.02M
Dividend YieldN/A
Average Volume (3M)2.90M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth6.30%
EPS Growth-208.64%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding920,625
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap1.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cuprina Holdings (Cayman) Limited Class A Business Overview & Revenue Model
Company Description
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its ...
Cuprina Holdings (Cayman) Limited Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.89K | 48.32K | 100.77K | 56.60K | 58.50K |
| Gross Profit | -645.00 | -3.02K | 36.60K | 19.98K | 23.06K |
| EBITDA | -4.56M | -1.43M | -994.12K | -1.06M | -489.44K |
| Net Income | -4.67M | -1.56M | -1.12M | -1.09M | -519.69K |
Balance Sheet | |||||
| Total Assets | 8.50M | 1.75M | 1.59M | 1.44M | 953.05K |
| Cash, Cash Equivalents and Short-Term Investments | 3.12M | 116.47K | 35.26K | 564.58K | 767.29K |
| Total Debt | 482.72K | 254.79K | 121.82K | 183.63K | 170.03K |
| Total Liabilities | 3.45M | 6.20M | 4.48M | 3.21M | 1.64M |
| Stockholders Equity | 5.06M | -4.46M | -2.90M | -1.78M | -683.52K |
Cash Flow | |||||
| Free Cash Flow | -9.19M | -1.26M | -1.61M | -1.87M | -224.72K |
| Operating Cash Flow | -9.13M | -1.24M | -1.54M | -1.85M | -221.86K |
| Investing Cash Flow | -58.23K | -21.88K | -67.98K | -31.28K | -2.86K |
| Financing Cash Flow | 12.23M | 1.34M | 1.08M | 1.68M | 991.39K |
Cuprina Holdings (Cayman) Limited Class A Risk Analysis
Cuprina Holdings (Cayman) Limited Class A disclosed 69 risk factors in its most recent earnings report. Cuprina Holdings (Cayman) Limited Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cuprina Holdings (Cayman) Limited Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.02M | -3.09 | ― | ― | 6.30% | -208.64% | |
44 Neutral | $7.81M | -1.40 | -102.39% | ― | 356.16% | 62.82% | |
42 Neutral | $3.26M | -0.09 | ― | ― | ― | 76.55% | |
41 Neutral | $6.98M | -0.13 | -709.51% | ― | -84.76% | 79.01% |
* Healthcare Sector Average
CUPR
Cuprina Holdings (Cayman) Limited Class A
4.37
-41.23
-90.42%
GOVX
GeoVax Labs
1.34
-22.26
-94.32%
HCWB
HCW Biologics
1.09
-3.48
-76.15%
CLDI
Calidi Biotherapeutics
0.17
-3.20
-95.01%
PBM
Psyence Biomedical
3.15
-26.60
-89.41%
ASBP
Aspire Biopharma Holdings
6.58
-341.42
-98.11%
Cuprina Holdings (Cayman) Limited Class A Corporate Events
Cuprina Wins Landmark U.S. FDA 510(k) Clearance for MEDIFLY Maggots
Jun 15, 2026
On June 15, 2026, Cuprina Holdings (Cayman) Limited announced that its indirectly wholly owned unit Cuprina Pte. Ltd. received U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement the...
Cuprina Holdings Regains Nasdaq Compliance and Avoids Delisting
Jun 12, 2026
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology player specializing in chronic wound care, infertility, medical waste recycling and cosmeceuticals, has built its product portfolio around medical devices derived from natural mater...
Cuprina Holdings Shareholders Back Capital Overhaul and Enhanced Class B Voting Power
May 14, 2026
On May 14, 2026, Cuprina Holdings (Cayman) Limited held its 2026 Annual Meeting of Shareholders in Singapore and via webcast, where nine items of business were approved, including the appointment of JS Associate PLT as auditor for the fiscal year ...
Cuprina Holdings Sets May 14 AGM to Vote on Share Consolidation, Enhanced Class B Voting Rights and Capital Raise Flexibility
Apr 21, 2026
On April 21, 2026, Cuprina Holdings (Cayman) Limited filed a Form 6-K detailing arrangements for its annual general meeting to be held on May 14, 2026, in Singapore and via webcast, where shareholders can participate and vote. The meeting will con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.